Interferon beta in multiple sclerosis.
作者信息
Richards R G
出版信息
BMJ. 1996 Nov 9;313(7066):1159. doi: 10.1136/bmj.313.7066.1159.
Abstract
摘要
相似文献
1
Interferon beta in multiple sclerosis.多发性硬化症中的β干扰素。
BMJ. 1996 Nov 9;313(7066):1159. doi: 10.1136/bmj.313.7066.1159.
2
Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.β-1b干扰素在多发性硬化症中的应用。复发的重要性不可低估。
BMJ. 1996 Nov 16;313(7067):1263. doi: 10.1136/bmj.313.7067.1263b.
3
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.基于人群的干扰素β-1b治疗继发进展型多发性硬化症的成本效用研究。
BMJ. 1999 Dec 11;319(7224):1529-33. doi: 10.1136/bmj.319.7224.1529.
4
Trial of interferon-beta in multiple sclerosis stopped early.
Lancet. 1998 Feb 21;351(9102):573. doi: 10.1016/S0140-6736(98)23008-X.
5
Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.β-干扰素1b在多发性硬化症中的应用。制造商为该药物辩护。
BMJ. 1996 Nov 16;313(7067):1263. doi: 10.1136/bmj.313.7067.1263a.
6
Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.中和抗体与干扰素β-1b在复发缓解型多发性硬化症中的疗效
Mult Scler. 1997 Dec;3(6):402. doi: 10.1177/135245859700300610.
7
[Interferon-beta in multiple sclerosis--who is going to be treated?].
Tidsskr Nor Laegeforen. 1999 Sep 10;119(21):3114.
8
The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.干扰素β治疗的多发性硬化症患者中中和抗体的意义。
Arch Neurol. 2001 Aug;58(8):1297-8. doi: 10.1001/archneur.58.8.1297.
9
Beta interferon and multiple sclerosis: why the fuss?
QJM. 1996 Jan;89(1):1-3. doi: 10.1093/oxfordjournals.qjmed.a030132.
10
Treatment of multiple sclerosis with interferon beta-1 b.用β-1b干扰素治疗多发性硬化症。
Neurology. 1997 Aug;49(2):641-2. doi: 10.1212/wnl.49.2.641.
引用本文的文献
1
Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.多发性硬化症疾病修正疗法的成本效益：文献系统评价
Autoimmune Dis. 2012;2012:784364. doi: 10.1155/2012/784364. Epub 2012 Dec 6.
2
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.基于人群的干扰素β-1b治疗继发进展型多发性硬化症的成本效用研究。
BMJ. 1999 Dec 11;319(7224):1529-33. doi: 10.1136/bmj.319.7224.1529.
3
Linking health technology assessment to practice. Interview by Abi Berger.将卫生技术评估与实践相联系。阿比·伯杰访谈录
BMJ. 1999 Nov 13;319(7220):1292. doi: 10.1136/bmj.319.7220.1292.
4
The need for pharmacoeconomic evaluations in the NHS.英国国家医疗服务体系（NHS）中药物经济学评估的必要性。
Pharmacoeconomics. 1998 Sep;14(3):241-50. doi: 10.2165/00019053-199814030-00001.
本文引用的文献
1
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).肌肉注射干扰素β-1a治疗复发型多发性硬化症的疾病进展。多发性硬化症协作研究组（MSCRG）。
Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304.
2
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.干扰素β-1b对复发缓解型多发性硬化有效。II. 一项多中心、随机、双盲、安慰剂对照试验的MRI分析结果。英属哥伦比亚大学多发性硬化/MRI研究组和干扰素β多发性硬化研究组。
Neurology. 1993 Apr;43(4):662-7. doi: 10.1212/wnl.43.4.662.
3
Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.β-1b干扰素治疗多发性硬化症：随机对照试验的最终结果。IFNB多发性硬化症研究组和英属哥伦比亚大学MS/MRI分析组。
Neurology. 1995 Jul;45(7):1277-85.
4
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.共聚物1降低复发率并改善复发缓解型多发性硬化症的残疾状况：一项III期多中心、双盲、安慰剂对照试验的结果。共聚物1多发性硬化症研究组。
Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268.
5
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).评估多发性硬化症的神经功能损伤：扩展残疾状态量表（EDSS）
Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
Zotero 插件